Elan maintained by Merrill Lynch at sell

Elan Corp. plc was maintained by Merrill Lynch analyst Erica Whittaker at a sell rating, following multiple discussions with clinicians in the United States and Europe, plus a review of regulatory precedents regarding the fate of Tysabri, a multiple sclerosis drug in development with partner Biogen Idec Inc. At best, Merrill expects Tysabri to return to the market under restricted use. Elan shares Tuesday were down $0.17, or 1.92%, at $8.70 on volume of 4,788,400 shares versus the three-month running average of 6,879,980 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.